Studer’s work has helped reshape how researchers produce specialized human cells in the laboratory. His research has established methods for directing human pluripotent stem cells—cells capable of generating virtually every cell type in the body—toward specific neural identities. By controlling developmental signals in carefully timed sequences, scientists can produce populations of neurons and other neural cells that closely resemble those found in the human nervous system. These laboratory-generated cells are now used to investigate disease mechanisms, test potential medicines, and explore the possibility of replacing damaged tissue.

The technical importance of this approach extends far beyond cell production. Human pluripotent stem cell-derived neurons can provide experimental models that capture aspects of human biology often missed by animal systems or immortalized cell lines. Researchers can use them to study how genetic mutations affect neuronal development, how toxic proteins accumulate in neurodegenerative disorders, and how candidate drugs alter cellular function. Because the cells can be generated from different genetic backgrounds, they may also support more personalized approaches to disease modeling and therapeutic development.

Studer’s laboratory has placed particular emphasis on translating these discoveries into clinical applications. Among the most closely watched areas is Parkinson’s disease, in which the loss of dopamine-producing neurons contributes to tremor, rigidity, and impaired movement. Stem cell-derived dopamine neurons are being investigated as a potential replacement therapy designed to restore signaling within damaged brain circuits. Moving such treatments from the laboratory to patients requires rigorous control of cell identity, purity, genetic stability, immune compatibility, and long-term behavior after transplantation. Studer’s research has contributed to the scientific foundation for addressing these challenges.

“The ISSCR must be the place where stem cell researchers share their boldest ideas, where we help them navigate technical and ethical challenges, and where they find a community that will fight for the value of fundamental, high-risk research,” Studer said. “The ISSCR is your society. We are here to serve you, and we genuinely want to hear what is working, what we can do better, and what we should be bold enough to try next.” His remarks highlight the tension at the center of modern stem cell science: discoveries must be ambitious enough to transform medicine, but development must remain grounded in reproducible evidence and responsible oversight.

During his presidency, Studer will lead the society as it celebrates its 25th anniversary and prepares for its annual meeting in San Francisco next summer. The ISSCR represents researchers, clinicians, ethicists, and other specialists across more than 80 countries. Its work spans basic stem cell biology, organoid research, developmental biology, regenerative medicine, clinical translation, and the ethical governance of emerging technologies. The organization has become a major forum for setting scientific standards in a field where promising results can rapidly attract public attention and commercial investment.

ISSCR Chief Executive Officer Keith Alm said Studer embodies the innovation, rigor, and collaborative spirit associated with the organization. He added that Studer’s leadership would help strengthen the society’s international community while supporting the responsible development of stem cell research for patients. That responsibility is increasingly significant as experimental cell therapies move into clinical testing. Researchers must distinguish carefully between therapies supported by controlled trials and unproven interventions marketed directly to vulnerable patients, while regulators and scientists continue to define appropriate standards for manufacturing, monitoring, and informed consent.

Studer has been an active ISSCR leader for many years and previously served on the organization’s Board of Directors. In 2022, he received the ISSCR Achievement Award for transformative contributions to stem cell research and regenerative medicine. His presidency will also focus on supporting early-career scientists, whose work is essential to sustaining progress in a field that depends on expertise ranging from molecular genetics and bioengineering to immunology, neuroscience, and clinical medicine.

The society has also welcomed its newly elected officers and board members following the 2026 Annual Meeting. Fiona Doetsch, Ph.D., of the Biozentrum at the University of Basel in Switzerland, has begun her term as president-elect, while Malin Parmar, Ph.D., of Lund University in Sweden, has started her term as vice president. New board members include Jianping Fu, Ph.D., of the University of Michigan; Stefan Irion, M.D., of GC Therapeutics; and Kazuto Kato, Ph.D., of the University of Osaka. Shuibing Chen, Ph.D., of Weill Cornell Medicine, has been reappointed to the board. Together, the new leadership will guide a rapidly evolving scientific community whose next breakthroughs could determine whether stem cell biology becomes a dependable platform for treating conditions once considered irreversible.

Subject of Research: Stem cell research, regenerative medicine, neural cell development, and stem cell-based therapies for neurodegenerative disease

Article Title: Lorenz Studer Begins Term as President of the International Society for Stem Cell Research

Web References: International Society for Stem Cell Research — https://www.isscr.org/

Image Credits: ISSCR

Keywords: Stem cell research, pluripotent stem cells, regenerative medicine, Parkinson’s disease, neural cells, neurodegenerative disease, clinical research, translational research, ISSCR, Lorenz Studer

Janet Rossant, editor-in-chief of Stem Cell Reports, expressed her enthusiasm about the new appointments, emphasizing the importance of integrating diverse perspectives from a global community of stem cell scientists. The augmented board promises to uphold and elevate the journal’s role as a central platform for publishing groundbreaking research that propels the field forward. The multidisciplinary expertise encompassed by the new members enables a comprehensive evaluation of studies ranging from basic stem cell mechanisms to clinical regenerative medicine strategies, ensuring that the journal maintains its high standards for impactful science communication.

Among the newly appointed editorial board members are notable figures such as Bertie Göttgens of the Cambridge Stem Cell Institute in the United Kingdom, who is recognized for his insights into gene regulatory networks governing stem cell fate decisions. Likewise, Shimpei Gotoh from Japan’s Center for iPS Cell Research and Application adds profound clinical and translational expertise, particularly in induced pluripotent stem cell (iPSC) technologies. The inclusion of such internationally respected scientists underscores the journal’s commitment to representing the breadth of stem cell research on a global scale.

The expansion further includes distinguished researchers like Kristin Hope from Canada’s University Health Network’s Princess Margaret Cancer Centre, who focuses on cancer stem cells and their influence on tumor progression and therapy resistance. The diverse geographical representation of the new board—spanning from Australia’s Murdoch Children’s Research Institute to Harvard Medical School and institutions in China, Israel, and the United States—highlights Stem Cell Reports’ dedication to fostering a truly international dialogue in stem cell science.

Supporting these new appointments, the journal’s editorial team also features five eminent associate editors with extensive expertise in areas pivotal to the future of stem cell research. Anne Grapin-Botton, from Germany’s Max Planck Institute, brings a critical focus on pancreatic development and regeneration, particularly examining how tissue architecture influences cellular differentiation pathways. Haruhisa Inoue, based at Kyoto University in Japan, combines clinical insight with pioneering iPSC modeling to study neurodegenerative diseases, bridging the gap between stem cell research and neurologic therapies.

The editorial expertise continues with Martin Pera of The Jackson Laboratory in the USA, whose work on human pluripotent stem cells encompasses essential mechanisms of self-renewal and pluripotency, with direct implications for regenerative therapies and disease modeling. April Pyle from UCLA contributes advanced knowledge in muscle stem cells and CRISPR-based therapeutic approaches to neuromuscular disorders. Ludovic Vallier from the Berlin Institute of Health offers deep insights into liver biology and the creation of organoid models for metabolic disease research and cell-based interventions.

Stem Cell Reports operates under the auspices of the ISSCR and maintains a steadfast devotion to open access publishing, allowing unrestricted dissemination of high-caliber research. Its affiliation with Cell Press ensures that the journal benefits from a robust editorial infrastructure and visibility within the life sciences community. By integrating diverse research disciplines—ranging from molecular stem cell biology to ethical frameworks surrounding stem cell applications—the journal fosters an inclusive scientific conversation that influences policy, clinical practice, and future research directions.

The recent enhancement of the editorial board not only amplifies the journal’s scientific leadership but also strategically positions Stem Cell Reports to support and shape cutting-edge advancements in the stem cell field. The board’s collective expertise ensures thorough and thoughtful peer review, facilitating the publication of work that challenges existing paradigms and introduces innovative methodologies. As stem cell science continues to unlock new potentials in regenerative medicine and disease modeling, the journal serves as a vital forum for disseminating discoveries that bear significant translational promise.

This step forward highlights the journal’s mission to serve as the “voice of the field,” fostering a dynamic and inclusive community where emerging technologies, therapeutic strategies, and ethical dialogues intersect. By continuously adapting and expanding its editorial team, Stem Cell Reports demonstrates its dedication to maintaining relevance and leadership amid the rapidly evolving landscape of biomedical research.

Researchers and clinicians alike anticipate that the journal’s augmented editorial board will expedite the flow of transformative research findings from bench to bedside. Through rigorous scrutiny and collaborative editorial oversight, Stem Cell Reports ensures that published studies meet the highest scientific standards, providing reliable and impactful knowledge to the global community. The journal represents a beacon in the field, advocating for excellence, transparency, and innovation in stem cell research dissemination.

Additionally, the journal’s visibility on social media platforms like Twitter (@StemCellReports) expands its reach, engaging a wider audience from academic researchers to laypersons interested in regenerative medicine and stem cell therapies. This commitment to broad accessibility aligns with the ISSCR’s core mission to promote excellence and facilitate the ethical application of stem cell science to improve human health worldwide.

As the field of stem cell research transcends traditional disciplinary boundaries, Stem Cell Reports embodies an integrative approach that accommodates emerging discoveries across basic, translational, and clinical domains. The bolstered editorial board exemplifies the journal’s proactive strategy to anticipate and respond to scientific challenges and ethical considerations, ensuring that Stem Cell Reports remains at the forefront of this vibrant and impactful field of biomedical research.

Subject of Research: Stem Cell Biology and Regenerative Medicine

Article Title: Leading Stem Cell Scientists Join Expanded Editorial Board of Stem Cell Reports, Amplifying Global Expertise and Editorial Excellence

News Publication Date: Not specified in the original content

Web References:

• Stem Cell Reports Editorial Board and Team: https://www.cell.com/stem-cell-reports/editorial-board
• International Society for Stem Cell Research (ISSCR): http://www.isscr.org/
• Stem Cell Reports Twitter: https://twitter.com/stemcellreports

Image Credits: Rajan et al.

Keywords: Stem cell research, Academic publishing, Open access, Science communication, Science policy, Scientific publishing, Scientific organizations

The discovery of iPSCs marked a watershed moment in biomedical research, transcending the boundaries of traditional cell biology. By reprogramming somatic cells to revert to a pluripotent state, scientists have unlocked a reservoir of potential for regenerative medicine, disease modeling, and personalized therapies. This fundamental shift in cell reprogramming elucidates mechanisms underlying development and disease, igniting hope for novel interventions against previously unsurmountable medical challenges.

Reflecting on the profound impact of this discovery, Yamanaka remarked, “Twenty years ago, the discovery of induced pluripotent stem cells opened a new era in biomedical research.” His statement captures the essence of how iPSCs have not only expanded the horizons of scientific inquiry but have also catalyzed early-stage developments in therapeutic applications. The ability to generate patient-specific cell types with iPSCs stands as a pivotal breakthrough, promising advancements in personalized medicine, allowing for tailored treatment approaches based on individual genetic profiles.

More than just a meeting of minds, this symposium aims to foster an inclusive platform where researchers can share pioneering findings, cultivate collaborations, and inspire future directions within the field. The discussions will encapsulate diverse topics such as regenerative medicine, organoid technology, ethical considerations associated with stem cell utilization, and the intersection of artificial intelligence and cell biology. This multifaceted dialogue echoes the ISSCR’s commitment to advancing collective knowledge in stem cell research and its application.

Central to the symposium are the organizers whose expertise span across multiple domains within the scientific community. Jun Takahashi, from the Center for iPS Cell Research and Application (CiRA) at Kyoto University, along with Takanori Takebe from Cincinnati Children’s Hospital and Christine Mummery from Leiden University Medical Centre, co-lead this event alongside Emily Titus of Notch Therapeutics, forming a collaborative network aimed at celebrating and propelling the next phase of iPSC exploration.

Beyond the symposium, the ISSCR plans to mark this significant occasion with the release of a special issue in their open access journal, Stem Cell Reports. This publication will spotlight breakthrough achievements made possible by iPSC technology, highlighting the myriad of research developments that have emerged since its inception. This academic dissemination ensures that the knowledge gained during the symposium reaches a broad audience, reinforcing the commitment to transparency and accessibility in scientific communication.

In allowing attendees to engage actively with the latest findings, the symposium serves as a rich tapestry showcasing the evolution of stem cell science over the past two decades. Scientists and clinicians alike are eager to glean insights about current trajectories in research and anticipate the possibilities that lie ahead. By providing an environment conducive to learning and innovation, the forum intends to embolden researchers to explore uncharted territories in stem cell applications.

Participants of the symposium will also have the opportunity to network with influential figures in the field, fostering connections that extend beyond the confines of the symposium. Such interactions can catalyze collaborative research endeavors, generating synergies that can lead to impactful scientific advancements. The ISSCR emphasizes the importance of such gatherings in nurturing relationships among diverse stakeholders invested in the future of stem cell research.

A noteworthy aspect of the symposium’s objective is to address the ethical implications of advancements in iPSC technology. Ethical considerations are paramount in ensuring responsible research practices, particularly in the context of human research. There will be specialized sessions focusing on the regulatory landscape governing stem cell research, as well as discussions on public perceptions and the moral ramifications of manipulating cellular identity and potential applications of resulting therapies.

Adding to the celebratory atmosphere of the symposium, attendees can expect workshops and panels dedicated to exploring the latest technologies and methodologies complementing iPSC research. This hands-on experience not only enriches the scientific discussions but also equips researchers with practical knowledge to advance their work in the laboratory. By integrating emerging technologies into the symposium, the ISSCR emphasizes a forward-thinking approach to scientific dialogue.

As we count down to the symposium in Kyoto, anticipation builds around the newly forged pathways for collaboration and innovation in stem cell science. The ISSCR International Symposium stands as a testament to the incredible progress made in just twenty years, while simultaneously inspiring a future brimming with potential. As researchers converge to share their insights and celebrate their achievements, the dialogue generated here will undoubtedly ripple through the years to come, shaping the future landscape of regenerative medicine.

In preparation for this monumental event, those interested in attending the symposium can sign up for alerts regarding the program, ensuring they stay informed about the latest developments and opportunities to participate. Journalists are specifically invited to cover the stories that emerge from the symposium, contributing to the broader narrative that surrounds the ongoing evolution of stem cell research.

The ISSCR remains dedicated to upholding its mission of promoting excellence within the field, representing nearly 5,000 members from across 80 countries. This robust international representation highlights the global commitment to harnessing the power of stem cells for the betterment of human health. As the scientific community prepares for this landmark event, the contributions of researchers and their determination to push the envelope will redefine possibilities in the biomedical landscape.

The ISSCR International Symposium in 2026 is not just about celebrating past achievements, but also about envisioning the future of stem cell research. This significant event will set the stage for fresh ideas, innovative collaborations, and breakthroughs that will continue to propel our understanding and application of stem cell science toward monumental breakthroughs in health care and therapeutic interventions.

Subject of Research: Induced pluripotent stem cells (iPSCs)
Article Title: Celebrating 20 Years of iPSC Discovery at ISSCR Symposium 2026
News Publication Date: October 2023
Web References: International Society for Stem Cell Research, Stem Cell Reports
References: N/A
Image Credits: Kyoto University

Keywords: stem cell research, induced pluripotent stem cells, regenerative medicine, biomedical research, scientific collaboration, ethical considerations in research, organoid technology, personalized medicine, scientific symposium, Nakyo Japan, ISSCR, Shinya Yamanaka